Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fate Therapeutics, Inc.

https://fatetherapeutics.com/

Latest From Fate Therapeutics, Inc.

India's ImmunoACT Gears To Deliver CAR-T Therapy At Close To Transplant-Like Prices

ImmunoACT gets go-ahead in India for its CD19-targeted CAR-T cell therapy, which reported low toxicity and the absence of neurotoxicities in clinical trials. The product will come at a huge price differential compared to on-market therapies, offering new hope to several patients.

India Approvals

Nkarta’s AML Update Disappoints, But New Conditioning Regimen Might Improve Response

An awaited update on early data for a CAR-NK therapeutic shows disappointing efficacy and duration, but a different chemotherapy conditioning regimen for lymphodepletion is showing early promise in acute myeloid leukemia.

Clinical Trials ImmunoOncology

Allogene May Have Cracked The Off-The-Shelf CAR-T Problem

Allogeneic candidate’s durability is holding up thanks to a novel conditioning regimen, but Phase II data will be crucial test.

Commercial Clinical Trials

Janssen Gives Next-Gen CAR-Ts Another Shot After Fate Deal’s Collapse

A new collaboration with Cellular Biomedicine includes a CD19/CD20-directed bispecific CAR-T in Phase I development for B-cell non-Hodgkin lymphomas.

Deals ImmunoOncology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Tfinity Therapeutics, Inc.
UsernamePublicRestriction

Register